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Abstract: A relatively simple and effective method to follow the movement of 
pharmaceutical preparations such as vaccines in biodistribution studies is to radiolabel the 
components. Whilst single radiolabelling is common practice, in vaccine systems 
containing adjuvants the ability to follow both the adjuvant and the antigen is favourable. 
To this end, we have devised a dual-radiolabelling method whereby the adjuvant 
(liposomes) is labelled with 3H and the antigen (a subunit protein) with 125I. This model is 
stable and reproducible; we have shown release of the radiolabels to be negligible over 
periods of up to 1 week in foetal calf serum at 37 ºC. In this paper we describe the 
techniques which enable the radiolabelling of various components, assessing stability and 
processing of samples which all for their application in biodistribution studies. 
Furthermore we provide examples derived from our studies using this model in 
tuberculosis vaccine biodistribution studies.  
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1. Introduction 
1.1. The origins and applications of radioisotopes 
The history of using radioisotopes as tracer molecules dates back to 1913 when George De Hevesy 
was struggling to separate a mixture of lead and Radium D. Unbeknown to him, this was an impossible 
feat as Radium D is actually a lead isotope (Pb210) and therefore inseparable. However, it was his 
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struggles with this situation with led (no pun intended) to the first use of radioisotopes as tracer 
molecules [1]. In 1935 De Hevesy published his works showing that radioisotopes could be used as 
tracer molecules in biological systems [2]. Nowadays public exposure to radioisotopes includes both 
therapeutic and diagnostic uses, for example barium meals and for treatment of cancers. In the 
laboratory setting radioisotopes are generally used as tracer molecules in both in v itro and in vivo  
experimentation. With regards to their pharmaceutical application, radioisotopes are particularly useful 
for studying the pharmacokinetics and/or biodistribution of substances. By associating a small ‘tracer’ 
amount of radioisotope at a known concentration to drugs or vaccines, the presence and quantity of the 
initial drug or vaccine can be determined.  
1.2. Radiolabelling in the lab 
A common problem encountered by researchers in this field is the ability to acquire pre-labelled 
substances, and whilst many life science and technology companies produce generic radiolabeled 
compounds such as albumins, amino acids and cholesterol, the ability to self-label the molecule of 
choice is appealing as it allows the user to have more control over aspects such as quantity required, 
concentration of both the drug/vaccine and the radioisotope, and the date required (as radioisotope 
decay and/or breakdown from associated molecules is often a problem).  
When choosing to radiolabel a substance, the type of radioactive emission, energy emitted and half-
life of the radioisotope must all be considered. Table 1 outlines some radioisotopes frequently used in 
biosciences and their respective properties. The most commonly used radioisotopes are 3H and 14C 
primarily due to their abundance, facility to conjugate to biological molecules and extensively 
documented use. Both are beta (β) particle emitters with moderate energy ranges and considerably 
long half lives. However as both radioisotopes emit β-particles and their energy ranges significantly 
overlap, their combined use in the same application is often difficult as detection instruments must 
separate one radioisotope from the other. To overcome this problem, a combination of β- and γ-
emitters can be used, or the use of two β-emitters but with substantially different energy ranges, such 
as 3H and 32P. A further advantage of combining 32P with other radioisotopes in dual-radiolabelling 
studies is that 32P emits β-particles at such a high energy level that a scintillation cocktail is not 
required (for all other β-particle emitters a scintillant is required to transfer energy emitted from the 
radioisotope to the detector). Known as Cherenkov counting, this method shares a similarity with 
radioactive detection from γ-emitters in that their activity can be detected directly in the sample 
without the need of chemical or heat degradation to produce clear and colourless samples.  
Table 1. Common laboratory radioisotopes and their uses. 
Radioisotope Decay emission Half-life Application 
3H β 12.3 years Amino acid labelling, cell proliferation assays 
14C β 5730 years Amino acid labelling 
35S β 87.4 days Nucleotide, amino acid labelling 
51Cr γ 27.7 days Cytotoxicity assays 
32P β 14.3 days Nucleotide labelling 
33P β 25.4 days Nucleotide labelling 
90Y β, γ 2.67 days Therapeutic 
125I γ 60.1 days Protein labelling 
Pharmaceutics 2010, 2                                   
 
93
1.3. Application of radioisotopes in vaccine studies 
Vaccine development in recent years has focused on the use of subunit proteins as opposed to killed 
or attenuated microorganisms, predominantly due to safety. However, whilst these vaccines display 
improved safety profiles, often their ability to successfully immunise the host is reduced. Adjuvants 
are therefore increasingly common additions to subunit vaccines and whilst they improve the 
immunogenicity of the subunit protein, the method in which they work is varied and still not fully 
understood making their classification somewhat problematic [3]. Like in many other sub-domains of 
pharmaceutical research, the end goal would be the development of a system of rules that could limit 
the need to extensively screen drug candidates and combinations. With regards to adjuvants, due to 
their varied results with different antigens it is not possible to have one adjuvant for numerous antigens 
– each antigen-adjuvant combination is treated as a separate drug system. In an attempt to increase our 
understanding of these systems, their distribution in vivo can be followed. In fact, EU guidelines on 
adjuvants destined for human vaccines recommend completing distribution studies for a 
comprehensive understanding of the method of adjuvant action [4].  
Work in our lab has focussed on the use of liposomes as adjuvants and transfection agents for a 
range of disease models [5–8]. The bilayered structure of liposomes composed of hydrophobic and 
hydrophilic domains provides a versatile structure; molecules such as cholesterol or 
immunomodulators can intercalate into the hydrophobic bilayer or be incorporated between bilayers in 
the hydrophilic aqueous domain. Furthermore, inclusion of charged lipids into the bilayer results in a 
liposome surface charge therefore allowing electrostatic interactions with proteins and DNA. This 
flexible bilayer structure makes liposomes ideal systems for addition of commercially available 
radiolabelled lipids. Through appropriate lipid choice, the addition of ‘tracer’ amounts of such 
radiolabelled lipids will not significantly alter the physical or chemical structure of the liposome, a 
property which is especially important with regards to liposomes as adjuvants. In contrast to dyes 
included in the internal aqueous domain which may ‘leak’ from the liposome, the use of membrane 
incorporated lipids is more appealing as retention of lipids within liposome bilayers is generally high 
until major liposome degradation occurs.  
In addition to tracing the adjuvant, detection of the antigen is equally important if a greater 
understanding of how these two components work together is to be had. However the epitope of 
subunit protein vaccine antigens must be retained for the vaccine to successfully immunise the host, 
therefore, radiolabelling provides a preferable alternative to fluorescent labelling as unlike the addition 
of fluorophores to molecules, which are often bulky moieties, can have a significant impact on 
properties such as pI, molecular weight, solubility and protein folding, the addition of small 
radioisotopes generally does not alter the structure or kinetics of the molecule in question. 
Furthermore, fluorescent labelling is highly dependent on pH and the presence of principally primary 
amine functional groups [9]. This in itself can pose a problem in formulations using Tris buffer which 
is a primary amine and therefore cannot be used in any stages concerning fluorescence labelling. 
Whilst several groups describe the use of singular radiolabelled components in biodistribution and 
pharmacokinetic studies [10–14], there are few documented dual-radiolabelled studies. With regard to 
reducing studies on animals, dual-radiolabelling as opposed to single component radiolabelling is more 
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favourable as the number of animals required is reduced and is therefore in keeping with the 3 R’s of 
refinement, reduction and replacement.  
1.4. Practicalities of using radioisotopes 
The stability of pre-radiolabelled compounds and molecules varies greatly between compounds and 
is an important consideration when conducting pharmacokinetic and biodistribution studies. Addition 
of sufficiently active but old and decomposing radiolabelled compounds will result in analogous 
results with ‘free label’ giving inaccurate readings. Typically gel filtration columns, centrifugation or 
dialysis are used to remove unbound radioisotopes after self-radiolabelling of substances.  A 
disadvantage therefore of self-labelling compounds destined for in vivo  studies is the reduction in 
sterility with each additional step.  
For the purpose of demonstrating the application of radiolabelling vaccines, the methods outlined 
below describe liposomes composed of the cationic lipid DDA and the immunomodulatory molecule 
TDB. This system, termed DDA:TDB, has been extensively analysed in our lab [6,15–18] and the 
results shown here were used to investigate the biodistribution of this liposome system as an adjuvant 
in vaccine studies. 
2. Materials and Methods 
2.1. Materials 
Dimethyldioctadecylammonium bromide (DDA) and trehalose 6,6’-dibehenate (TDB) were 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).  Methanol and chloroform (both HPLC 
grade) were purchased from Fisher Scientific (Leicestershire, UK). Tris-base, obtained from IDN 
Biomedical, Inc (Aurora, Ohio) was used to make Tris buffer and adjusted to pH 7.4 using HCl; unless 
stated otherwise Tris buffer was used at 10mM, pH 7.4. Hydrogen peroxide, ovalbumin, Sephadex™ 
G-75 and bicinchoninic acid protein assay (BCA) components were purchased from Sigma Aldrich 
(St. Louis, MO). Ag85B-ESAT-6 was a kind gift from Statens Serum Institut, Denmark. Foetal calf 
serum (FCS) was from Biosera, UK. Dialysis membrane (12-14 kDa pore size) was from Medicell 
International Ltd, UK. For radiolabelling, l-3-phosphatidyl[N-methyl-3H]choline, 1,2-dipalmitoyl (3H-
DPPC) was obtained from GE Healthcare (Amersham, UK), Pierce iodination tubes were from Pierce 
Biotechnology (Rockford, IL) and 125I (NaI in NaOH solution), SOLVABLE™ and Ultima Gold™ 
scintillation fluid were purchased from Perkin Elmer (Waltham, MA).   
2.2. Radiolabelling of liposomes 
To follow the movement of liposomes in vivo  a stable radioactive tracer component was added to 
the liposomes which can integrate into the bilayer. The commercially available tritiated lipid DPPC 
was chosen as it was paramount that the addition of the tracer lipid did not affect the physicochemical 
properties of DDA:TDB. For this particular compound the proportion of 3H to DPPC was high (3 
TBq/mmol) therefore enabling extremely low levels of 3H-DPPC to be used. The highest ratio of 3H-
DPPC:DDA (or other lipid) used throughout our studies was for in vivo  experiments via the 
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intramuscular (i.m) injection route which involved relatively high amounts (<200 kBq) of 3H-DPPC. 
In this instance the concentration was 500 ng 3H-DPPC:5 mg DDA/mL.  
Liposomes were produced using the relatively simple method known as lipid-film hydration [19]. 
DDA (1.25 mg) and TDB (0.25 mg) were dissolved in a mixture of chloroform and methanol (9:1 v/v) 
in a round bottomed flask (rbf). 3H-DPPC (25 ng, dissolved in a 1:1 v/v mixture of toluene:ethanol) 
was added to the rbf. The solvents were removed using a roto-evaporator set over a water bath at  
37 ºC. This process took approximately 20 min after which the resulting lipid-film was flushed with N2 
for 5 min to ensure complete solvent removal. Nine hundred microlitres of Tris buffer (10 mM, pH 
7.4) was added to the rbf to rehydrate the lipid film. The rbf was covered with Parafilm® and held in a 
water bath (60 ºC) with frequent vortexing for the following 20 min. For experiments requiring 
antigen, 100 μL of antigen (dissolved in an appropriate buffer to a concentration 10-fold higher than 
required) was added to the cooled liposomes so that adsorption via electrostatic interactions may take 
place. For in vivo  studies, the concentration of liposomes was increased so that an intramuscular 
injection (50 μL) contained 250 μg DDA, 50 μg TDB and 25 ng 3H-DPPC.  
2.3. Radiolabelling of antigen 
To radiolabel protein antigen, Pierce iodination tubes containing Pierce iodination reagent (formally 
known as IODO-GEN tubes) were used. The tubes contain an oxidizing reagent which converts NaI 
into a reactive iodine molecule that can insert into the tyrosol group of tyrosine amino acids (Figure 1).  
Figure 1. Diagram showing iodination of the amino acid tyrosine using Pierce oxidising 
reagent present in Pierce iodination tubes. Two possible iodination sites exist on tyrosine at 
the ortho ring position either side of the hydroxyl group [20].  
 
For efficient iodination the antigenic protein must therefore contain an adequate number of tyrosine 
amino acids, however for proteins which contain few tyrosine groups the Bolton-Hunter reagents can 
be used to introduce iodinatable sites. The iodination reaction is pH dependent with the optimum range 
being pH 6.5–8 and a 15% reduction in labelling efficiency with a pH decline of one unit [21]. It is 
therefore important to consider the protein and the buffer in which it is dissolved before carrying out 
iodination using Pierce iodination tubes. We have used the model antigen ovalbumin (OVA) which 
readily dissolves in Tris buffer (pH 7.4) and contains nine tyrosine groups for iodination to take place. 
Other examples of proteins we have used for radiolabelling are shown in Table 2.  
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Table 2. Selected proteins and their physical characteristics with relation to 125I-
radiolabelling.  
Protein Size 
(kDa) 
pI No Tyrosine 
residues 
125I-labelling 
Buffer/pH 
125I-labelling 
efficiency 
% adsorption to DDA:TDB 
liposomes  
OVA 45 4.5 9 Tris/7.4 +++ 88 %a 
BSA 66 4.7 21 Tris/7.4 +++ N/D 
Lysozyme 14.7 11 3 Tris/4 ++ 29 %b, [22] 
Ag85B-ESAT-6 44 4.9 13 Tris/7.4 +++ 97 %b, [22] 
a Determined using the BCA assay; b determined using 125I-radiolabelling; N/D, not determined. 
Iodination of proteins is a two step process: firstly protein and NaI are added to an iodination tube 
and left for approximately 1 h for the 125I to be incorporated into tyrosine groups; secondly free 
unbound 125I must be removed. For this latter process we used gel filtration chromatography using 
Sephadex™ G-75 beads. To make the column, 1 g of Sephadex™ G-75 was rehydrated overnight at 
room temperature with 20 mL Tris buffer (10 mM, pH 7.4). The bead slurry was poured into a 5 ml 
glass pipette; glass was used as opposed to plastic to minimise protein binding to the column and to 
facilitate decontamination of the pipette after use. To radiolabel the protein, the amount of protein and 
125I required was calculated with the rule that all the protein and approximately 70 % of the 125I would 
be recovered from the column. These values were calculated in preliminary experiments whereby 1 mg 
OVA and 1 MBq 125I were radiolabelled and the unbound 125I was removed using a gel column (made 
as described above). Samples were recovered from the column in 1 minute intervals and each sample 
(approximately 250 μL) was measured for protein content using the BCA assay. The amount of OVA 
in each sample was calculated using an OVA standard curve and plotted against the amount of iodine 
(in counts per minute, CPM) per sample.   
For in vivo  immunisation studies, 2 μg Ag85B-ESAT-6 and approximately 100kBq 125I was 
required per dose (intramuscular injection). Therefore to make sufficient for 40 doses, for example,  
80 μg Ag85B-ESAT-6 (100 μl at 800 μg/mL) and 5.71 MBq 125I (40 doses at 100 kBq each, plus 30 % 
which is counted as ‘free unbound’ 125I) was added to an iodination tube. This was left for 1h with 
intermittent swirling to ensure that the protein and 125I solutions were fully exposed to the iodination 
reagent on the tube walls. To remove the unbound 125I, the tap on the gel filtration column was opened 
and the total volume of protein-125I added to the top of the gel taking care to ensure that the solution 
flowed into the gel directly and quickly. The column was flushed with Tris buffer (10 mM, pH 7.4) 
and samples collected directly into γ-vials at 1 min intervals. Forty samples were collected as this 
represented the total column volume (~10 mL) and therefore anything obtained after this would be 
interacting in a non-size dependent manner with the gel medium. Each sample was counted for the 
presence of 125I using a γ-counter and Ag85B-ESAT-6 using the BCA assay. Samples positive for both 
125I and Ag85B-ESAT-6 were pooled and the volume adjusted to 80 μg/mL Ag85B-ESAT-6 so that 
upon mixing with an equal volume of liposomes for i.m. vaccination (50 μL) the amount of Ag85B-
ESAT-6 would be 2 μg/dose.  
2.4. Stability studies using 3H-labelled liposomes or 125I-labelled antigen 
One of the issues with radiolabelling is when quantifying their presence in samples you are actually 
measuring the radioisotope with the assumption it remains associated with the 
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molecule/protein/liposome in question. Therefore it is important to ensure that the radioisotope stays 
associated with the molecule/protein/liposome, both ‘on the bench’ and in v ivo. For the purpose of 
biodistribution studies, we devised methods to investigate the efficiency of 3H-DPPC retention in the 
liposome membrane, and the retention/release profile of 125I-labelled Ag85B-ESAT-6 from liposomes. 
Both these studies were undertaken at 37 ºC in a solution of 50% foetal calf serum to simulate the in 
vivo environment.  
To measure 3H-DPPC retention in the lipid bilayer, liposomes composed of DDA (250 μg), TDB 
(50 μg) and 3H-DPPC (25 ng) were produced as described in section 2.2 using a volume of 500 μL 
Tris buffer to rehydrate the lipid film. A volume of 250 μL liposomes with 250 μL of FCS/Tris buffer 
(50:50 v/v) were placed inside a dialysis membrane with a pore size of 12-14kDa. The membrane was 
sealed and placed in a 50 mL conical tube containing 40 mL FCS/Tris buffer (50:50 v/v). Dialysis was 
undertaken at 37 ºC in a shaking water bath with 400 μL samples of the dialysing buffer being 
removed at various time points and being replaced with 400 μL of FCS:Tris (50:50 v/v) to maintain 
sink conditions. For 3H detection, 10 mL of Ultima Gold™ scintillation fluid was added to each  
400 μl sample and counted on a scintillation counter using a basic tritium counting protocol. 
125I-labelled protein can be used to measure protein adsorption to liposomes and the release profile 
from liposomes in simulated in vivo  conditions. As opposed to dialysis we used centrifugation to 
measure these properties and one liposome dose (equivalent to 250 μg lipid) was prepared for each 
time-point of interest. Liposomes were produced without the presence of the 3H tracer DPPC and only 
rehydrated in half the normal volume so that upon addition of the 125I-Ag85B-ESAT-6 (20 μg/mL) the 
final lipid concentration would be 250 μg in 200 μL. 125I-Ag85B-ESAT-6 was left to adsorb to the 
liposomes for 1 h following which 200 μl was placed in a thick-walled eppendorf (Beckman Coulter, 
Polyallomer 1.5 mL tubes) with 800 μL of FCS:Tris (50:50 v/v). The eppendorf was vortexed well and 
either incubated at 37 ºC for release studies or processed straight away to determine percentage protein 
adsorption. For processing, each sample was spun at 125,000 × g, 4 ºC for 30 min followed by one 
wash using Tris buffer. The two supernatants and pellet were counted for 125I presence using a gamma 
counter. The percentage protein adsorption and/or release from liposomes were determined based on 
the total amount of 125I recovered.   
2.5. Processing of tissues containing 125I and 3H 
Biodistribution of antigens and liposomes within animal models can be traced by collecting various 
tissue samples and/or blood at selected time intervals. Quantification of 125I is relatively simple as γ-
rays can pass through solid tissue and do not require a scintillant to transfer the energy emitted from 
the radioisotope to the detector in the machine. Detection of 3H is somewhat more problematic for a 
number of reasons. Firstly a scintillant (scintillation cocktail) is required as scintillation counters do 
not directly measure the radioactive particles produced but instead measure light photons which result 
from excitation of the scintillant. Secondly the energy emitted by radioisotopes can be absorbed by the 
scintillant and other chemicals added to the sample for the purposes of digestion and bleaching. This is 
termed chemical quench and the efficiency in detecting light photons produced by the scintillant is also 
reduced when colour is present in the sample (colour quenching). Finally, the counting efficiency of 
3H is poor (typically less than 60%) so having additional factors present such as chemical and colour 
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quench further decrease this value. Therefore, good tissue preparation is paramount and identical 
processing of each sample is recommended so that chemical quench is kept stable. Samples containing 
haemoglobin and its derivatives (e.g., blood, liver) have higher levels of colour quench than lighter 
tissues such as serum, muscle or brain. Incomplete tissue digestion is also common for the digestive 
tract due to the presence of fats or faeces containing cellulose.  
The protocol described below has been used for the digestion of brain, blood, heart, lung, kidney, 
liver, spleen, lymph node, small intestine, muscle and dermis/hypodermis tissues. Typically samples 
collected were less than 100 mg in weight however for the heart, spleen and kidney the whole organ 
was processed and occasionally this was over 100 mg. Furthermore, as previous experiments [23] were 
focussed on the retention of vaccines at the site of injection (quadriceps muscle), all muscle taken from 
the lower leg was processed (between 200–300 mg). For the processing of blood, less than 100 mg was 
preferential due to the strong colour quenching. All the samples collected were fully digested and 
colourless using the protocol described below, the exception being that some of the blood and liver 
samples had a slight yellow tinge.  
Upon retrieval of the tissues, the material was counted directly for the presence of 125I-radiolabelled 
protein using a Cobra™ CPM Auto-Gamma® counter (Packard Instruments Company inc., IL, USA). 
To verify that the presence of undigested tissue and whole organs did not affect the count rate, all 
samples from original experiments were counted for 125I prior and post tissue digestion. There was no 
difference in the results therefore samples containing 125I can be counted prior or post digestion. One 
and a half millilitres of Solvable™ (solubilising agent) was added to each sample and a lid put on the 
vial. The vials were heated to 50 ºC with frequent agitation of the tubes to aid Solvable™ penetration 
of the tissues. Once fully solubilised and cooled the tissue solutions were transferred to plastic 
scintillation vials; whilst glass scintillation vials may also be used, plastic vials are reported to have 
lower background counts and are less expensive and easier to dispose of. Two hundred microlitres of 
H2O2 (Sigma Aldrich) was added to each sample to bleach the solution thereby minimising colour 
quench. The samples were heated at 50 ºC until fully decolourised and foaming had stopped. Once 
cooled 10 mL of Ultima Gold™ scintillation fluid was added to each vial and the samples counted 
using a standard 3H detection protocol (Figure 2). 
Figure 2. Schematic showing the processes involved in tissue processing to detect 125I and 
3H presence following injection of dual-radiolabelled components. 
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3. Results and Discussion 
3.1. Radiolabelling of proteins  
As previously mentioned, one of the main benefits of radiolabelling is its non-intrusive nature 
whereby the original molecule is not physically or chemically altered. Figure 3 shows how gel 
filtration can be used to separate 125I-protein (in this case, OVA) from free, unbound 125I. As 125I-
radiolabelling of OVA does not alter the physicochemical properties of OVA, all the OVA added to 
the gel filtration column is eluted over a small volume range (~12 to 20 min; Figure 3) and this elution 
time/volume was not influenced by the presence of the 125I-label (Figure 3). Commonly the binding 
efficiency of 125I to protein is not 100% efficient and therefore due to its reduced size excess ‘free’ 125I 
elutes at a slower rate: with the outlined set-up free 125I eluted 26 to 40 min after addition to the 
column (Figure 3). 
Using the above described method, a range of 125I-radiolabelled proteins can be produced and used 
to investigate protein loading within in range of systems including liposomes [6,15,23], niosomes [16] 
and microspheres [15,18]. Using this method we have also shown that the protein antigens Ag85B-
ESAT-6, CtH1 and lysozyme can all adsorb to cationic liposomes to varying degrees [22,23] with the 
pI of the proteins playing a significant role in surface adsorption.   
Figure 3. Gel filtration was used to separate unbound 125I from OVA antigen. The graph 
shows the presence of 125I (left y-axis, -♦-) and OVA (right y-axis, -■-) in 40 samples 
collected from a Sephadex™ G-75 column measuring approximately 8 cm.   
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3.2. Radiolabelling of liposomes 
In order to verify that liposome membrane degradation with release of the radiolabel tracer did not 
occur upon exposure of liposomes to the in vivo environment, stability studies were conducted at 37 ºC 
in a high protein environment. Dialysis was used to investigate the retention of the lipid label 3H-
DPPC in liposomal bilayers. A dialysis membrane with a pore size large enough to allow large 
molecules to pass, yet retain liposomes, was chosen. Figure 4 shows the release profile of 3H-DPPC 
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from cationic DDA:TDB liposomes; less than 10% of the 3H-DPPC radiolabel was detected in the 
dialysis buffer over the initial 96 h. The dialysis membrane had a molecular weight cut off (MWCO) 
of 12-14 kDa and whilst 3D measurements such as molecular size cannot be exactly correlated with 
2D measurements such as length, the pore size was large enough to allow the movement of DPPC 
(MW 733) but retain liposomes which had a vesicle diameter of approximately 500 nm. As a rough 
guide, a MWCO of 12-14 kDa translates to a 2D measurement of approximately  
2 nm. Consequently, liposomes of approximately 500 nm will be retained whilst allowing DPPC and 
small micellar systems to pass through. With regard to free DPPC and micelle formation, the quantities 
of 3H-DPPC outlined in section 2.4 result in a DPPC molarity of 0.42 nM (assuming there is 100% 3H-
DPPC immediately). This is just below the cited CMC of DPPC 0.46 nM so therefore it is safe to 
assume that even if all the 3H-DPPC left the liposomes immediately, micelle formation would  
not occur. 
Figure 4. Release profile of 3H-DPPC from DDA:TDB liposomes when kept in simulated 
in vivo conditions (37 ºC, 50% FCS). Results denote mean (n = 3) ± SD. 
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3.3. Measuring dual-radiolabelled preparations in tissues 
Herein we have described how 3H-radiolabelled liposomes and 125I-radiolabelled antigen can be 
used separately to study the stability of vaccines under conditions stimulating the in vivo environment. 
Whilst the application of dual-radiolabelled vaccines provides an ideal method to measure the 
pharmacokinetic properties and tissue distribution of both the liposome and antigen, the presence of 
two radioisotopes in the same tissue is problematic for accurate 3H quantification as 125I is also 
detected using scintillation counting (however 3H is not detected using γ-counting). To overcome this 
problem we devised a method whereby the 125I could be factored out by the use of a standard curve. 
Triplicate samples of 125I starting at an activity equivalent to the dose administered in vivo (~100 kBq) 
were diluted 2-fold until background levels (~20 cpms) were reached. These samples were counted 
using a γ-counter and then transferred and processed as the tissue samples would be (see section 2.5). 
The samples were then counted on a scintillation counter using the same 3H detection protocol as used 
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for the tissue samples. A plot of the cpm values derived from the γ-counter (x-axis) against the cpm 
values derived from the scintillation counter (y-axis) was made and the line of best fit and equation 
derived for samples below 50,000 cpm (~2% of the dose or less) and those above 50,000 cpm (~2% of 
the dose or more). These two equations were used to calculate the effective interference that the 125I 
would have on the 3H values determined by scintillation counting. We found that the efficiency of 125I 
counting using our scintillation counters was approximately half of that seen by the γ-counter; however 
for each separate biodistribution study conducted a new 125I standard curve was produced as the 
machines counting efficacy can change and is also dependent on the amount of 125I in the sample. To 
investigate whether this relationship was linear, known volumes of 3H were added to the serially 
diluted 125I samples and counted on the scintillation counter. The results showed a linear relationship 
(Figure 5) indicating that there is no quenching effect between the two radioisotopes and that the above 
equation method to remove interfering 125I counts is valid.  
Figure 5. Graph showing how addition of 3H (2-25 kBq) adds linearly to 125I detection 
when measured using a scintillation counter. 3H was added to serially diluted 125I samples 
representing between 0.5–100% of the 125I dose. The R2 value for all data sets was equal to 
or more than 0.998. Results denote mean (n = 3) ± SD. 
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3.4. Tracking the In Vivo Fate of Radiolabelled Systems 
The method described for the processing of tissues and determination of the relevant quantities of 
3H-radiolabelled liposomes and 125I-radiolabelled protein is suitable for a range of tissues. Figure 6 
shows the proportions of each vaccine component detected in a selection of tissues. For the given 
example, the vaccine shows a characteristic depot-effect at the site of injection (SOI). However low 
levels (<0.01% of the injected dose) can also be detected in the lymph nodes. With respect to depot-
forming vaccines, our studies have focussed on obtaining data from the site of injection as long term 
antigen retention at the SOI is one of the described mechanisms of adjuvant action [3]. We have 
conducted numerous studies whereby DDA:TDB liposomes adsorbing antigen were used as a control 
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formulation. Figure 7 shows the strong reproducibility of these experiments and highlights the ability 
of this control liposome formulation to cause an antigen depot-effect at the SOI for a period of at least 
14 days.   
Figure 6. Dual-radiolabelling offers the possibility of detecting both 3H-labelled liposomes 
and 125I-labelled protein in a wide selection of tissues. A range of tissues were collected 
one day post injection and processed to determine the proportion of each radioisotope. 
Popliteal lymph node, PLN; brachial lymph node, BLN; site of injection, SOI. Results 
denote mean (n = 3) ± SD.  
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Figure 7. Reproducibility of dual-radiolabelling experiments involving 3H-radiolabelled 
liposomes (A) and 125I-radiolabelled protein (B). Four different experiments were 
conducted using the same liposome formulation as a control to measure the percentage of 
the injected dose still present at the injection site on days 1, 4 and 14 post injection. Results 
denote mean (n = 3 or 5) ± SD.  
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4. Conclusion   
To conclude, we have shown that the use of two readily accessible radioisotopes, 3H and 125I, can be 
used simultaneously to detect vaccine components after injection. Using dialysis and centrifugation 
techniques we have shown that the radiolabel does not dissociate significantly from either the liposome 
or protein after exposure to an environment simulating in v ivo conditions. Finally, this dual-
radiolabelling is reproducible and applicable for vaccine studies for the detection of vaccines in a 
range of tissues.   
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